Aquestive Therapeutics (NASDAQ:AQST) Rating Increased to Hold at Wall Street Zen

Aquestive Therapeutics (NASDAQ:AQST) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital set a $6.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Finally, Piper Sandler lifted their price objective on shares of Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $8.80.

Aquestive Therapeutics Stock Down 0.9%

NASDAQ:AQST opened at $4.22 on Friday. The stock has a market cap of $515.01 million, a P/E ratio of -5.41 and a beta of 1.61. The business’s 50-day moving average price is $4.22 and its two-hundred day moving average price is $5.19. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The firm had revenue of $13.02 million during the quarter, compared to the consensus estimate of $13.28 million. On average, equities research analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Aquestive Therapeutics by 30.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after purchasing an additional 1,333,627 shares in the last quarter. Federated Hermes Inc. raised its holdings in Aquestive Therapeutics by 159.4% in the fourth quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock worth $13,132,000 after buying an additional 1,249,044 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics by 6,233.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock worth $7,569,000 after buying an additional 1,153,175 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in Aquestive Therapeutics in the 3rd quarter valued at approximately $5,918,000. Finally, Wells Fargo & Company MN boosted its stake in Aquestive Therapeutics by 804.6% during the 4th quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock valued at $7,678,000 after purchasing an additional 1,057,145 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Key Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Aquestive reiterated FY‑2026 revenue guidance of $46.0M–$50.0M and plans a commercial launch for Anaphylm with a ~75‑rep sales force and an expanded medical affairs team — these items support near‑term revenue upside if launch execution is successful. Aquestive plans 75‑rep Anaphylm launch
• Neutral Sentiment: Company released Q4 results and an earnings‑call presentation/transcript that provide more detail on revenue mix, commercialization plans and guidance; these materials will be used by investors to reassess model assumptions. Q4 2025 earnings call transcript
• Negative Sentiment: Q4 results missed expectations: EPS loss of $0.26 vs. consensus of ($0.13) and revenue slightly below estimates — the miss raises short‑term earnings risk and increases scrutiny on margins and burn. Q4 results and estimates
• Negative Sentiment: Multiple law firms announced investigations and several class‑action complaints were filed alleging that Aquestive misled investors about the timing of FDA approval for Anaphylm (PDUFA date-related disclosures). Legal exposure and potential damages or distraction to management are downside catalysts for the stock. Robbins LLP stockholder alert
• Negative Sentiment: Additional litigation notices/investigations were publicized today (Bernstein Liebhard, Holzer & Holzer, Gainey McKenna & Egleston, Faruqi & Faruqi), amplifying legal and reputational risk and likely adding selling pressure while matters progress. Bernstein Liebhard investor alert
• Negative Sentiment: Analyst commentary and a TipRanks note flagged new risk disclosures (AI execution risk and competitive threats) that could pressure future margins and R&D success probabilities. TipRanks AI execution risks

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.